01
Flagship · 6 of 7 live
Weight loss and metabolic
GLP-1 receptor agonists and adjacent metabolic peptides; the most clinically validated class on the site and roughly 80% of category demand.
Where the category stands in May 2026 — what's available, who to trust, what costs what. 22-min read, medically reviewed.
Read the guideAn independent overview of the compounded-GLP-1 telehealth market and the providers we cover — market size, what the FDA changed, and an honest read on each.
View the provider overviewOverview & reviewsPrimers for newcomers and deep dives for the curious. The foundation articles are published; more are in the pipeline.
View all Learn articlesWhat compounded and branded semaglutide and tirzepatide actually cost, from each provider's own published pricing.
Every peptide we cover, organized by what it actually does. Clinical evidence, regulatory status, and what to ask a licensed clinician — written for adults who want the honest version.
GLP-1 receptor agonists and adjacent metabolic peptides; the most clinically validated class on the site and roughly 80% of category demand.
Melanocortin agonists, oxytocin, kisspeptin; libido and reproductive signaling pathways.
Tissue-repair peptides used for rehab, gut and joint healing — most studied in animal models, increasingly used off-label in athletes and post-surgical recovery.
GH secretagogues and growth-hormone-releasing peptides used for lean mass, recovery, and body composition.
Anxiolytic and nootropic peptides; longer research history outside the US, thinner FDA footprint.
Telomere, mitochondrial, and immune-related compounds; mostly research-stage outside Tesamorelin and Sermorelin.
Collagen and pigment-pathway peptides; mix of approved cosmetic ingredients and research compounds.
| Compound | Category | Best for | Onset | |
|---|---|---|---|---|
| A | ||||
| AOD-9604 › Modified GH fragment | weight-loss | Targeted fat loss adjunct | 6-8 weeks | |
| Argireline › Acetyl hexapeptide-8 | skin-hair | Topical wrinkle reduction | 4-6 weeks | |
| B | ||||
| BPC-157 › Pentadecapeptide | recovery | Tissue repair, gut health | 1-2 weeks | |
| C | ||||
| Cerebrolysin › Brain peptide complex | cognitive | Neuroprotection (research-stage) | 3-4 weeks | |
| CJC-1295 › GHRH analog (long-acting) | performance | Sustained GH release | 3-5 weeks | |
| D | ||||
| Dihexa › Angiotensin IV analog | cognitive | Synaptogenesis (preclinical) | Preclinical | |
| E | ||||
| Epitalon › Tetrapeptide, pineal | longevity | Telomere / circadian | Cycle-based | |
| G | ||||
| GHK-Cu › Copper tripeptide-1 | skin-hair | Skin repair, collagen | 4-8 weeks | |
| GLP-1 › Incretin hormone & drug class | weight-loss | Class explainer — hormone, drugs, pipeline | Varies | |
| I | ||||
| Ipamorelin › GH secretagogue | performance | Lean mass, recovery | 2-4 weeks | |
| K | ||||
| Kisspeptin › KISS1-derived | sexual-wellness | Reproductive hormone signaling | 1-4 weeks | |
| KPV › α-MSH(11-13) tripeptide | recovery | Inflammation (preclinical only) | No human data | |
| L | ||||
| Liraglutide › GLP-1 agonist | weight-loss | Weight loss (older generation) | 4-8 weeks | |
| M | ||||
| Matrixyl › Palmitoyl pentapeptide-4 | skin-hair | Collagen production (topical) | 6-12 weeks | |
| Melanotan II › α-MSH analog | sexual-wellness | Libido, pigmentation | 1-3 weeks | |
| MOTS-c › Mitochondrial-derived | longevity | Metabolic, mitochondrial | 4-6 weeks | |
| N | ||||
| NAD+ › Coenzyme (not a peptide) | longevity | Cellular energy, anti-aging | 2-4 weeks | |
| O | ||||
| Oxytocin › Nonapeptide | sexual-wellness | Bonding, intimacy | Acute | |
| P | ||||
| PT-141 › Bremelanotide | sexual-wellness | Desire (FDA-approved as Vyleesi) | 30-60 min | |
| PTD-DBM › Wnt pathway peptide | skin-hair | Hair regrowth (preclinical) | Preclinical | |
| R | ||||
| Retatrutide › GLP-1/GIP/glucagon triple agonist | weight-loss | Investigational — largest trial weight loss | Investigational | |
| S | ||||
| Selank › Heptapeptide | cognitive | Anxiolytic, focus | Days | |
| Semaglutide › GLP-1 agonist (compounded) | weight-loss | Weight loss, blood sugar | 4-8 weeks | |
| Semax › ACTH(4-10) analog | cognitive | Focus, neuroprotection | Days | |
| Sermorelin › GHRH analog | longevity | Sleep, recovery, body comp | 4-6 weeks | |
| T | ||||
| TB-500 › Thymosin Beta-4 fragment | recovery | Tissue repair, inflammation | 2-3 weeks | |
| Tesamorelin › GHRH analog (FDA-approved) | weight-loss | Visceral fat reduction | 8-12 weeks | |
| Thymalin › Thymus polypeptides | longevity | Immune restoration (research) | Cycle-based | |
| Tirzepatide › GLP-1/GIP dual agonist | weight-loss | Weight loss (dual agonist) | 4-6 weeks | |